Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shareholders of Tandem Diabetes would probably like to forget the past six months even happened. The stock dropped 54.1% and ...

Stifel Nicolaus analyst Mathew Blackman maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target ...

In trading on Wednesday, shares of Tandem Diabetes Care Inc (Symbol: TNDM) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $19.16 per share.

Tandem Diabetes Care, Inc. has a fifty-two week low of $17.64 and a fifty-two week high of $53.69. Insider Activity In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm’s ...

Amsterdam played host to this year's edition of the International Conference on Advanced Technologies & Treatments for ...

Natixis Advisors LLC grew its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 3.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 65,678 shares of the ...

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is ...

Hambright covers the Healthcare sector, focusing on stocks such as Insulet, Intuitive Surgical, and Tandem Diabetes Care. According to TipRanks, Hambright has an average return of 8.3% and a 66.10% ...

These stocks offer a middle ground with... Tandem Diabetes Care, Inc. (NASDAQ:TNDM) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate ...